Results from a fairly recent survey of hospitals caring for pediatric patients were used to construct a national

antibiogram for the years 2010 and 2011 [10]. With the exceptions of aztreonam and gentamicin, reported susceptibility rates for isolates of P. aeruginosa in that report were similar to those in our last period of observation. While such national averages may be helpful in settings where a local antibiogram cannot be prepared, local antibiograms are nonetheless the best resource in guiding empiric prescribing decisions. Conclusion In summary, the susceptibility of pediatric isolates of P. aeruginosa to a number of antibiotics remained relatively stable over a 7-year period despite major changes in utilization of several of these drugs. Thus, large increases in utilization of at least some antibiotics CX-6258 ic50 are not uniformly associated with subsequent changes in bacterial resistance. Acknowledgments No funding or sponsorship was received for this study or publication of this article. The selleck chemicals author thanks Carrie Alderman, PharmD for her assistance in the collection and organization

of data for this analysis. The named author meets the ICMJE criteria for authorship for this manuscript, takes responsibility for the integrity of the work as a whole, and has given final approval for the version to be published. Conflict of interest John Bosso declares that he has no conflicts of interest. Compliance with ethics guidelines The study was approved by the institution’s Institutional Review Board. The analysis in this article is based on existing data and does not involve any new studies of human or animal subjects performed by any of the authors. Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. Electronic supplementary material Below is the link to the electronic supplementary

PtdIns(3,4)P2 material. Supplementary material 1 (PDF 213 kb) References 1. Bosso JA. The impact of antibiotic management on resistance. Pharmacotherapy. 2004;24:224S–31S.PubMedCrossRef 2. Mauldin PD, Salgado CD, Durkalski VL, Bosso JA. Nosocomial infections due to Methicillin-resistant S. aureus and Vancomycin-resistant Enterococcus: relationships with antibiotic use and cost drivers. Ann Pharmacother. 2008;42:317–26.PubMedCrossRef 3. Plüss-Suard C, Pannatier A, Kronenberg A, Mühlemann K, Zanetti G. Impact of antibiotic use on carbapenem resistance in Pseudomonas aeruginosa: is there a role for antibiotic diversity? Antimicrob Agents Chemother. 2013;57:1709–13.PubMedCentralPubMedCrossRef 4. Martin C, Ofotokun I, Rapp R, et al. Results of an www.selleckchem.com/products/17-AAG(Geldanamycin).html antimicrobial control program at a university hospital. Am J Health Syst Pharm. 2005;62:732–8.PubMed 5. Mohr JF, Jones A, Ostrosky-Zeichner L, Wanger A, Tillotson G.